Company Overview - RxSight, Inc. (NASDAQ:RXST) was founded in 1997 and is based in Aliso Viejo, California, specializing in adjustable intraocular lenses for cataract surgery, enabling post-operative vision correction [4] Financial Performance - During its third-quarter 2025 earnings call, RxSight narrowed its full-year revenue guidance to a range of $125 million to $130 million, an increase from the previous guidance of $120 million to $130 million [3] - The company highlighted ongoing progress in its international rollout, particularly in Asia and Europe, supported by regulatory approvals and investments in commercial infrastructure [3] Market Analysis - William Blair initiated coverage of RxSight with a Market Perform rating and no price target, citing stalled sales growth in 2025 after strong adoption from early users between 2021 and 2024 [1] - The firm noted that evidence of sustained commercial reacceleration is necessary, despite the stock trading at a discount to peers [1]